Details of the Drug

General Information of Drug (ID: DMITX1G)

Drug Name
Citalopram derivative 1
Synonyms PMID29334795-Compound-59
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 324.4
Topological Polar Surface Area (xlogp) 3.2
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Clearance
The systemic clearance of drug is 330 mL/min [1]
Elimination
12-23% of an oral dose of citalopram is found unchanged in the urine, while 10% of the dose is found in the faeces [1]
Half-life
The concentration or amount of drug in body reduced by one-half in 35 hours [2]
Metabolism
The drug is metabolized via the liver [3]
Vd
The volume of distribution (Vd) of drug is 12 L/kg [1]
Chemical Identifiers
Formula
C20H21FN2O
IUPAC Name
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
Canonical SMILES
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
InChI
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
InChIKey
WSEQXVZVJXJVFP-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2771
ChEBI ID
CHEBI:77397
CAS Number
59729-33-8
DrugBank ID
DB00215
TTD ID
D0R6LF
ACDINA ID
D00133

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Inhibitor [4]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
Serotonin transporter (SERT) DTT SLC6A4 8.76E-01 7.18E-05 6.19E-04
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Citalopram derivative 1
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Citalopram derivative 1 and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [20]
Coadministration of a Drug Treating the Disease Different from Citalopram derivative 1 (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Methylene blue. Acquired methaemoglobinaemia [3A93] [21]
Glimepiride DM5FSJA Moderate Increased risk of hypoglycemia by the combination of Citalopram derivative 1 and Glimepiride. Acute diabete complication [5A2Y] [22]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Citalopram derivative 1 and Repaglinide. Acute diabete complication [5A2Y] [22]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Citalopram derivative 1 and Glibenclamide. Acute diabete complication [5A2Y] [22]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Citalopram derivative 1 and Tolazamide. Acute diabete complication [5A2Y] [22]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Citalopram derivative 1 and Nateglinide. Acute diabete complication [5A2Y] [22]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Citalopram derivative 1 and Insulin-glulisine. Acute diabete complication [5A2Y] [22]
Acetohexamide DMR6N7H Moderate Increased risk of hypoglycemia by the combination of Citalopram derivative 1 and Acetohexamide. Acute diabete complication [5A2Y] [22]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Citalopram derivative 1 and Insulin-aspart. Acute diabete complication [5A2Y] [23]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Citalopram derivative 1 and Glipizide. Acute diabete complication [5A2Y] [22]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Ivosidenib. Acute myeloid leukaemia [2A60] [24]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Midostaurin. Acute myeloid leukaemia [2A60] [24]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Idarubicin. Acute myeloid leukaemia [2A60] [24]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Daunorubicin. Acute myeloid leukaemia [2A60] [24]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Arn-509. Acute myeloid leukaemia [2A60] [24]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Gilteritinib. Acute myeloid leukaemia [2A60] [24]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Oliceridine. Acute pain [MG31] [25]
Terfenadine DM4KLPT Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [24]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Citalopram derivative 1 and Tacrine. Alzheimer disease [8A20] [24]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Citalopram derivative 1 and Galantamine. Alzheimer disease [8A20] [24]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Citalopram derivative 1 and Rivastigmine. Alzheimer disease [8A20] [24]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Metronidazole. Amoebiasis [1A36] [26]
Inotersen DMJ93CT Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Inotersen. Amyloidosis [5D00] [27]
Ranolazine DM0C9IL Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Ranolazine. Angina pectoris [BA40] [24]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Bepridil. Angina pectoris [BA40] [24]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Dronedarone. Angina pectoris [BA40] [24]
Nifedipine DMSVOZT Minor Decreased metabolism of Citalopram derivative 1 caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [28]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [24]
Buspirone DMBS632 Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Buspirone. Anxiety disorder [6B00-6B0Z] [29]
Methylphenobarbital DMDSWAG Moderate Antagonize the effect of Citalopram derivative 1 when combined with Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [30]
Hydroxyzine DMF8Y74 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [24]
Promazine DMZAL7W Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Promazine. Appearance/behaviour symptom [MB23] [24]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Cilostazol. Arterial occlusive disease [BD40] [27]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Posaconazole. Aspergillosis [1F20] [24]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Citalopram derivative 1 and Levalbuterol. Asthma [CA23] [31]
Terbutaline DMD4381 Major Increased risk of ventricular arrhythmias by the combination of Citalopram derivative 1 and Terbutaline. Asthma [CA23] [32]
Zafirlukast DMHNQOG Minor Decreased metabolism of Citalopram derivative 1 caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [28]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Pirbuterol. Asthma [CA23] [32]
Isoetharine DMITSEH Moderate Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Isoetharine. Asthma [CA23] [32]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Citalopram derivative 1 and Formoterol. Asthma [CA23] [32]
Atomoxetine DM5L6HI Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Atomoxetine. Attention deficit hyperactivity disorder [6A05] [24]
Lisdexamfetamine DM6W8V5 Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [25]
Methylphenidate DM7SJD6 Moderate Decreased metabolism of Citalopram derivative 1 caused by Methylphenidate. Attention deficit hyperactivity disorder [6A05] [33]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Desipramine. Attention deficit hyperactivity disorder [6A05] [25]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Ofloxacin. Bacterial infection [1A00-1C4Z] [24]
Ciprofloxacin XR DM2NLS9 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [24]
Dalfopristin DM4LTKV Minor Decreased metabolism of Citalopram derivative 1 caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [28]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Clarithromycin. Bacterial infection [1A00-1C4Z] [24]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [24]
Chloramphenicol DMFXEWT Minor Decreased metabolism of Citalopram derivative 1 caused by Chloramphenicol mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [28]
Linezolid DMGFPU2 Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Linezolid. Bacterial infection [1A00-1C4Z] [34]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Gemifloxacin. Bacterial infection [1A00-1C4Z] [24]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Norfloxacin. Bacterial infection [1A00-1C4Z] [24]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Levofloxacin. Bacterial infection [1A00-1C4Z] [24]
Moxifloxacin DMU8V4S Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Moxifloxacin. Bacterial infection [1A00-1C4Z] [24]
Troleandomycin DMUZNIG Minor Decreased metabolism of Citalopram derivative 1 caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [28]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Lomefloxacin. Bacterial infection [1A00-1C4Z] [24]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Telithromycin. Bacterial infection [1A00-1C4Z] [24]
Lamotrigine DM8SXYG Moderate Antagonize the effect of Citalopram derivative 1 when combined with Lamotrigine. Bipolar disorder [6A60] [30]
Pexidartinib DMS2J0Z Major Decreased metabolism of Citalopram derivative 1 caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [35]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Loperamide. Bowel habit change [ME05] [36]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Eribulin. Breast cancer [2C60-2C6Y] [24]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Lapatinib. Breast cancer [2C60-2C6Y] [24]
Tucatinib DMBESUA Minor Decreased metabolism of Citalopram derivative 1 caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [28]
Palbociclib DMD7L94 Minor Decreased metabolism of Citalopram derivative 1 caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [28]
Letrozole DMH07Y3 Major Decreased metabolism of Citalopram derivative 1 caused by Letrozole mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Tamoxifen DMLB0EZ Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Tamoxifen. Breast cancer [2C60-2C6Y] [24]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Toremifene. Breast cancer [2C60-2C6Y] [24]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Bosutinib. Breast cancer [2C60-2C6Y] [24]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [37]
Mannitol DMSCDY9 Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Mannitol. Bronchiectasis [CA24] [38]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Grepafloxacin. Bronchitis [CA20] [24]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Sotalol. Cardiac arrhythmia [BC9Z] [24]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [24]
Pregabalin DMDVP3B Moderate Antagonize the effect of Citalopram derivative 1 when combined with Pregabalin. Chronic obstructive pulmonary disease [CA22] [30]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Citalopram derivative 1 and Vilanterol. Chronic obstructive pulmonary disease [CA22] [31]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Citalopram derivative 1 and Salmeterol. Chronic obstructive pulmonary disease [CA22] [32]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Arformoterol. Chronic obstructive pulmonary disease [CA22] [32]
Phenylbutazone DMAYL0T Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Phenylbutazone. Chronic pain [MG30] [27]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Citalopram derivative 1 and Dihydrocodeine. Chronic pain [MG30] [39]
Ketoprofen DMRKXPT Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Ketoprofen. Chronic pain [MG30] [27]
Morphine DMRMS0L Moderate Additive CNS depression effects by the combination of Citalopram derivative 1 and Morphine. Chronic pain [MG30] [39]
Levetiracetam DMTGDN8 Moderate Antagonize the effect of Citalopram derivative 1 when combined with Levetiracetam. Chronic pain [MG30] [30]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Levomilnacipran. Chronic pain [MG30] [29]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Anisindione. Coagulation defect [3B10] [27]
Irinotecan DMP6SC2 Minor Decreased metabolism of Citalopram derivative 1 caused by Irinotecan mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [40]
Oxaliplatin DMQNWRD Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Oxaliplatin. Colorectal cancer [2B91] [24]
Isoproterenol DMK7MEY Major Increased risk of ventricular arrhythmias by the combination of Citalopram derivative 1 and Isoproterenol. Conduction disorder [BC63] [32]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Citalopram derivative 1 and Olopatadine. Conjunctiva disorder [9A60] [41]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Halothane. Corneal disease [9A76-9A78] [24]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Sevoflurane. Corneal disease [9A76-9A78] [24]
Remifentanil DMZTXCH Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Remifentanil. Corneal disease [9A76-9A78] [29]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Probucol. Coronary atherosclerosis [BA80] [24]
Ardeparin DMYRX8B Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Ardeparin. Coronary thrombosis [BA43] [27]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Methadone. Cough [MD12] [24]
Dextromethorphan DMUDJZM Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Dextromethorphan. Cough [MD12] [29]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Clofazimine. Crohn disease [DD70] [24]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Mifepristone. Cushing syndrome [5A70] [24]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Pasireotide. Cushing syndrome [5A70] [24]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Osilodrostat. Cushing syndrome [5A70] [24]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Citalopram derivative 1 caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [42]
Ivacaftor DMZC1HS Minor Decreased metabolism of Citalopram derivative 1 caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [28]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Citalopram derivative 1 and Ethanol. Cystitis [GC00] [41]
MK-8228 DMOB58Q Minor Decreased metabolism of Citalopram derivative 1 caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [28]
Danaparoid DM6CLBN Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Danaparoid. Deep vein thrombosis [BD71] [27]
Rivaroxaban DMQMBZ1 Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Rivaroxaban. Deep vein thrombosis [BD71] [27]
Aprepitant DM053KT Minor Decreased metabolism of Citalopram derivative 1 caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [28]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Sertraline. Depression [6A70-6A7Z] [25]
Trimipramine DM1SC8M Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Trimipramine. Depression [6A70-6A7Z] [25]
Cyclobenzaprine DM1YBRM Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Cyclobenzaprine. Depression [6A70-6A7Z] [29]
Imipramine DM2NUH3 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Imipramine. Depression [6A70-6A7Z] [25]
Fluoxetine DM3PD2C Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Fluoxetine. Depression [6A70-6A7Z] [25]
Nortriptyline DM4KDYJ Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Nortriptyline. Depression [6A70-6A7Z] [25]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Vilazodone. Depression [6A70-6A7Z] [29]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Nefazodone. Depression [6A70-6A7Z] [29]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Selegiline. Depression [6A70-6A7Z] [43]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Vortioxetine. Depression [6A70-6A7Z] [29]
Duloxetine DM9BI7M Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Duloxetine. Depression [6A70-6A7Z] [29]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Milnacipran. Depression [6A70-6A7Z] [29]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Escitalopram. Depression [6A70-6A7Z] [44]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Tranylcypromine. Depression [6A70-6A7Z] [43]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Desvenlafaxine. Depression [6A70-6A7Z] [29]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Phenelzine. Depression [6A70-6A7Z] [43]
Clomipramine DMINRKW Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Clomipramine. Depression [6A70-6A7Z] [25]
Trazodone DMK1GBJ Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Trazodone. Depression [6A70-6A7Z] [25]
Amitriptyline DMK7F9S Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Amitriptyline. Depression [6A70-6A7Z] [25]
Amoxapine DMKITQE Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Amoxapine. Depression [6A70-6A7Z] [25]
Mirtazapine DML53ZJ Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Mirtazapine. Depression [6A70-6A7Z] [25]
Protriptyline DMNHTZI Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Protriptyline. Depression [6A70-6A7Z] [25]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Doxepin. Depression [6A70-6A7Z] [25]
Maprotiline DMPWB7T Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Maprotiline. Depression [6A70-6A7Z] [24]
Venlafaxine DMR6QH0 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Venlafaxine. Depression [6A70-6A7Z] [25]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [24]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Ingrezza. Dystonic disorder [8A02] [24]
Fenfluramine DM0762O Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [29]
Zonisamide DM0DTF7 Moderate Antagonize the effect of Citalopram derivative 1 when combined with Zonisamide. Epilepsy/seizure [8A61-8A6Z] [30]
Felbamate DM1V5ZS Major Decreased metabolism of Citalopram derivative 1 caused by Felbamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Oxcarbazepine DM5PU6O Major Decreased metabolism of Citalopram derivative 1 caused by Oxcarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Mephenytoin DM5UGDK Moderate Antagonize the effect of Citalopram derivative 1 when combined with Mephenytoin. Epilepsy/seizure [8A61-8A6Z] [30]
Methsuximide DM6L5VO Moderate Antagonize the effect of Citalopram derivative 1 when combined with Methsuximide. Epilepsy/seizure [8A61-8A6Z] [30]
Valproate DMCFE9I Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Valproate. Epilepsy/seizure [8A61-8A6Z] [30]
Ethosuximide DMDZ9LT Moderate Antagonize the effect of Citalopram derivative 1 when combined with Ethosuximide. Epilepsy/seizure [8A61-8A6Z] [30]
Tiagabine DMKSQG0 Moderate Antagonize the effect of Citalopram derivative 1 when combined with Tiagabine. Epilepsy/seizure [8A61-8A6Z] [30]
Phenacemide DMOHS9P Moderate Antagonize the effect of Citalopram derivative 1 when combined with Phenacemide. Epilepsy/seizure [8A61-8A6Z] [30]
Paramethadione DMR5ZUP Moderate Antagonize the effect of Citalopram derivative 1 when combined with Paramethadione. Epilepsy/seizure [8A61-8A6Z] [30]
Brivaracetam DMSEPK8 Moderate Antagonize the effect of Citalopram derivative 1 when combined with Brivaracetam. Epilepsy/seizure [8A61-8A6Z] [30]
Lacosamide DMVM6QR Moderate Antagonize the effect of Citalopram derivative 1 when combined with Lacosamide. Epilepsy/seizure [8A61-8A6Z] [30]
Rufinamide DMWE60C Moderate Antagonize the effect of Citalopram derivative 1 when combined with Rufinamide. Epilepsy/seizure [8A61-8A6Z] [30]
Ethotoin DMXWOCP Moderate Antagonize the effect of Citalopram derivative 1 when combined with Ethotoin. Epilepsy/seizure [8A61-8A6Z] [30]
Vigabatrin DMYT0OG Moderate Antagonize the effect of Citalopram derivative 1 when combined with Vigabatrin. Epilepsy/seizure [8A61-8A6Z] [30]
Carbamazepine DMZOLBI Minor Increased metabolism of Citalopram derivative 1 caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [45]
Eslicarbazepine DMZREFQ Moderate Antagonize the effect of Citalopram derivative 1 when combined with Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [30]
Timolol DM3NXRU Moderate Decreased metabolism of Citalopram derivative 1 caused by Timolol mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [46]
Ethacrynic acid DM60QMR Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Ethacrynic acid. Essential hypertension [BA00] [38]
Bendroflumethiazide DM7EVLC Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Bendroflumethiazide. Essential hypertension [BA00] [38]
Benzthiazide DMQWZ0H Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Benzthiazide. Essential hypertension [BA00] [38]
Mefenamic acid DMK7HFI Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Mefenamic acid. Female pelvic pain [GA34] [27]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Tazemetostat. Follicular lymphoma [2A80] [27]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Solifenacin. Functional bladder disorder [GC50] [24]
Tolterodine DMSHPW8 Minor Decreased metabolism of Citalopram derivative 1 caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [47]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Citalopram derivative 1 caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [48]
Itraconazole DMCR1MV Minor Decreased metabolism of Citalopram derivative 1 caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [28]
Clotrimazole DMMFCIH Minor Decreased metabolism of Citalopram derivative 1 caused by Clotrimazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [28]
Miconazole DMPMYE8 Minor Decreased metabolism of Citalopram derivative 1 caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [28]
Ketoconazole DMPZI3Q Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Ketoconazole. Fungal infection [1F29-1F2F] [24]
Omeprazole DM471KJ Major Decreased metabolism of Citalopram derivative 1 caused by Omeprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [35]
Cimetidine DMH61ZB Major Decreased metabolism of Citalopram derivative 1 caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [35]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Cisapride. Gastro-oesophageal reflux disease [DA22] [24]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Sunitinib. Gastrointestinal stromal tumour [2B5B] [24]
Avapritinib DMK2GZX Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Avapritinib. Gastrointestinal stromal tumour [2B5B] [27]
Acetazolamide DM1AF5U Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Acetazolamide. Glaucoma [9C61] [38]
Methazolamide DM7J2TA Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Methazolamide. Glaucoma [9C61] [38]
Dichlorphenamide DMH7IDQ Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Dichlorphenamide. Glaucoma [9C61] [38]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Sulfinpyrazone. Gout [FA25] [27]
Ergotamine DMKR3C5 Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Ergotamine. Headache [8A80-8A84] [29]
Spironolactone DM2AQ5N Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Spironolactone. Heart failure [BD10-BD1Z] [38]
Triamterene DM2HU9I Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Triamterene. Heart failure [BD10-BD1Z] [38]
Carvedilol DMHTEAO Moderate Decreased metabolism of Citalopram derivative 1 caused by Carvedilol mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [46]
Chlorothiazide DMLHESP Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Chlorothiazide. Heart failure [BD10-BD1Z] [38]
Furosemide DMMQ8ZG Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Furosemide. Heart failure [BD10-BD1Z] [38]
Amiloride DMRTSGP Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Amiloride. Heart failure [BD10-BD1Z] [38]
Bumetanide DMRV7H0 Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Bumetanide. Heart failure [BD10-BD1Z] [38]
Hydroflumethiazide DMVPUQI Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Hydroflumethiazide. Heart failure [BD10-BD1Z] [38]
Boceprevir DMBSHMF Minor Decreased metabolism of Citalopram derivative 1 caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [28]
Telaprevir DMMRV29 Minor Decreased metabolism of Citalopram derivative 1 caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [28]
Isoniazid DM5JVS3 Major Decreased metabolism of Citalopram derivative 1 caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [35]
Rifampin DMA8J1G Moderate Increased metabolism of Citalopram derivative 1 caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [49]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Procarbazine. Hodgkin lymphoma [2B30] [43]
Indinavir DM0T3YH Minor Decreased metabolism of Citalopram derivative 1 caused by Indinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
Delavirdine DM3NF5G Major Decreased metabolism of Citalopram derivative 1 caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
Fosamprenavir DM4W9B3 Minor Decreased metabolism of Citalopram derivative 1 caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [24]
Nevirapine DM6HX9B Moderate Increased metabolism of Citalopram derivative 1 caused by Nevirapine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [26]
Cobicistat DM6L4H2 Minor Decreased metabolism of Citalopram derivative 1 caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [24]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [24]
Etravirine DMGV8QU Major Decreased metabolism of Citalopram derivative 1 caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [50]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [24]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [24]
Amprenavir DMLMXE0 Minor Decreased metabolism of Citalopram derivative 1 caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
Darunavir DMN3GCH Minor Decreased metabolism of Citalopram derivative 1 caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
Atazanavir DMSYRBX Minor Decreased metabolism of Citalopram derivative 1 caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
Ritonavir DMU764S Minor Decreased metabolism of Citalopram derivative 1 caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
Fenofibrate DMFKXDY Major Decreased metabolism of Citalopram derivative 1 caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [26]
BMS-201038 DMQTAGO Minor Decreased metabolism of Citalopram derivative 1 caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [28]
Nebivolol DM7F1PA Moderate Decreased metabolism of Citalopram derivative 1 caused by Nebivolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [46]
Verapamil DMA7PEW Minor Decreased metabolism of Citalopram derivative 1 caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [28]
Diltiazem DMAI7ZV Minor Decreased metabolism of Citalopram derivative 1 caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [28]
Indapamide DMGN1PW Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Indapamide. Hypertension [BA00-BA04] [38]
Trichlormethiazide DMHAQCO Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Trichlormethiazide. Hypertension [BA00-BA04] [38]
Metoprolol DMOJ0V6 Moderate Decreased metabolism of Citalopram derivative 1 caused by Metoprolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [46]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Hydrochlorothiazide. Hypertension [BA00-BA04] [38]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Dipyridamole. Hypertension [BA00-BA04] [27]
Conivaptan DM1V329 Minor Decreased metabolism of Citalopram derivative 1 caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [28]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Citalopram derivative 1 caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [51]
Temazepam DM02A65 Moderate Additive CNS depression effects by the combination of Citalopram derivative 1 and Temazepam. Insomnia [7A00-7A0Z] [26]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Citalopram derivative 1 and Polyethylene glycol. Irritable bowel syndrome [DD91] [24]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Citalopram derivative 1 and Phenolphthalein. Irritable bowel syndrome [DD91] [24]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Citalopram derivative 1 caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [49]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Citalopram derivative 1 and Porfimer Sodium. Lung cancer [2C25] [52]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Ceritinib. Lung cancer [2C25] [24]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Osimertinib. Lung cancer [2C25] [24]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Selpercatinib. Lung cancer [2C25] [24]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Halofantrine. Malaria [1F40-1F45] [24]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Chloroquine. Malaria [1F40-1F45] [24]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Hydroxychloroquine. Malaria [1F40-1F45] [24]
Quinine DMSWYF5 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Quinine. Malaria [1F40-1F45] [24]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Primaquine. Malaria [1F40-1F45] [24]
Mefloquine DMWT905 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Mefloquine. Malaria [1F40-1F45] [24]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [24]
Idelalisib DM602WT Minor Decreased metabolism of Citalopram derivative 1 caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [28]
IPI-145 DMWA24P Minor Decreased metabolism of Citalopram derivative 1 caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [28]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Arsenic trioxide. Mature B-cell lymphoma [2A85] [24]
Acalabrutinib DM7GCVW Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Acalabrutinib. Mature B-cell lymphoma [2A85] [27]
Ibrutinib DMHZCPO Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Ibrutinib. Mature B-cell lymphoma [2A85] [27]
Ponatinib DMYGJQO Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Ponatinib. Mature B-cell lymphoma [2A85] [27]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Vemurafenib. Melanoma [2C30] [24]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and LGX818. Melanoma [2C30] [24]
Danazol DML8KTN Minor Decreased metabolism of Citalopram derivative 1 caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [28]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Citalopram derivative 1 and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [53]
Zolmitriptan DM1IB4Q Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Zolmitriptan. Migraine [8A80] [29]
Dihydroergotamine DM5IKUF Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Dihydroergotamine. Migraine [8A80] [29]
Propranolol DM79NTF Moderate Decreased metabolism of Citalopram derivative 1 caused by Propranolol mediated inhibition of CYP450 enzyme. Migraine [8A80] [46]
Frovatriptan DM7RE8P Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Frovatriptan. Migraine [8A80] [29]
Rizatriptan DMDJMA3 Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Rizatriptan. Migraine [8A80] [29]
Naratriptan DMO50U2 Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Naratriptan. Migraine [8A80] [29]
Sumatriptan DMVYXR8 Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Sumatriptan. Migraine [8A80] [29]
Eletriptan DMW649X Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Eletriptan. Migraine [8A80] [29]
Flibanserin DM70DTN Moderate Decreased metabolism of Citalopram derivative 1 caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [54]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Panobinostat. Multiple myeloma [2A83] [24]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Citalopram derivative 1 and Thalidomide. Multiple myeloma [2A83] [55]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Citalopram derivative 1 and Siponimod. Multiple sclerosis [8A40] [26]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Citalopram derivative 1 and Fingolimod. Multiple sclerosis [8A40] [24]
Ozanimod DMT6AM2 Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Ozanimod. Multiple sclerosis [8A40] [56]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Romidepsin. Mycosis fungoides [2B01] [24]
Fedratinib DM4ZBK6 Major Decreased metabolism of Citalopram derivative 1 caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [35]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Nilotinib. Myeloproliferative neoplasm [2A20] [24]
Imatinib DM7RJXL Minor Decreased metabolism of Citalopram derivative 1 caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [28]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Dasatinib. Myeloproliferative neoplasm [2A20] [24]
Vorapaxar DMA16BR Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Vorapaxar. Myocardial infarction [BA41-BA43] [27]
Tirofiban DMQG17S Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Tirofiban. Myocardial infarction [BA41-BA43] [27]
Modafinil DMYILBE Major Decreased metabolism of Citalopram derivative 1 caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [35]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Droperidol. Nausea/vomiting [MD90] [24]
Prochlorperazine DM53SRA Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Prochlorperazine. Nausea/vomiting [MD90] [57]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Promethazine. Nausea/vomiting [MD90] [57]
Palonosetron DMBHMOX Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Palonosetron. Nausea/vomiting [MD90] [24]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Granisetron. Nausea/vomiting [MD90] [24]
Dolasetron DMMG26Z Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Dolasetron. Nausea/vomiting [MD90] [24]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Ondansetron. Nausea/vomiting [MD90] [24]
E-2007 DMJDYNQ Moderate Antagonize the effect of Citalopram derivative 1 when combined with E-2007. Neuropathy [8C0Z] [30]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Citalopram derivative 1 and Bupropion. Nicotine use disorder [6C4A] [24]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Entrectinib. Non-small cell lung cancer [2C25] [24]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Sibutramine. Obesity [5B80-5B81] [25]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Lorcaserin. Obesity [5B80-5B81] [58]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Dexfenfluramine. Obesity [5B80-5B81] [29]
Chlorthalidone DM4DMBT Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Chlorthalidone. Oedema [MG29] [38]
Polythiazide DMCH80F Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Polythiazide. Oedema [MG29] [38]
Urea DMUK75B Moderate Increased risk of hyponatremia by the combination of Citalopram derivative 1 and Urea. Oesophagitis [DA24] [38]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Levomethadyl Acetate. Opioid use disorder [6C43] [24]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Lofexidine. Opioid use disorder [6C43] [24]
Diclofenac DMPIHLS Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Diclofenac. Osteoarthritis [FA00-FA05] [27]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Rucaparib. Ovarian cancer [2C73] [24]
Pentazocine DM1XBHS Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Pentazocine. Pain [MG30-MG3Z] [29]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Citalopram derivative 1 and Dextropropoxyphene. Pain [MG30-MG3Z] [59]
Butorphanol DM5KYPJ Moderate Additive CNS depression effects by the combination of Citalopram derivative 1 and Butorphanol. Pain [MG30-MG3Z] [39]
Oxymorphone DM65AGJ Moderate Additive serotonergic effects by the combination of Citalopram derivative 1 and Oxymorphone. Pain [MG30-MG3Z] [39]
Aspirin DM672AH Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Aspirin. Pain [MG30-MG3Z] [37]
Etodolac DM6WJO9 Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Etodolac. Pain [MG30-MG3Z] [27]
Diflunisal DM7EN8I Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Diflunisal. Pain [MG30-MG3Z] [27]
Ibuprofen DM8VCBE Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Ibuprofen. Pain [MG30-MG3Z] [27]
Nabumetone DMAT2XH Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Nabumetone. Pain [MG30-MG3Z] [27]
Levorphanol DMGS80V Moderate Additive CNS depression effects by the combination of Citalopram derivative 1 and Levorphanol. Pain [MG30-MG3Z] [39]
Hydromorphone DMHP21E Moderate Additive CNS depression effects by the combination of Citalopram derivative 1 and Hydromorphone. Pain [MG30-MG3Z] [39]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Citalopram derivative 1 and Dezocine. Pain [MG30-MG3Z] [39]
Codeine DMJX6ZG Moderate Decreased metabolism of Citalopram derivative 1 caused by Codeine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [60]
Nalbuphine DMOSQGU Moderate Additive CNS depression effects by the combination of Citalopram derivative 1 and Nalbuphine. Pain [MG30-MG3Z] [39]
Buprenorphine DMPRI8G Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Buprenorphine. Pain [MG30-MG3Z] [24]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Citalopram derivative 1 and Hydrocodone. Pain [MG30-MG3Z] [39]
Piroxicam DMTK234 Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Piroxicam. Pain [MG30-MG3Z] [27]
Meperidine DMX4GND Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Meperidine. Pain [MG30-MG3Z] [29]
Oxycodone DMXLKHV Moderate Additive serotonergic effects by the combination of Citalopram derivative 1 and Oxycodone. Pain [MG30-MG3Z] [39]
Trimethadione DM0Q8MZ Moderate Antagonize the effect of Citalopram derivative 1 when combined with Trimethadione. Pancreatic cancer [2C10] [30]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Triclabendazole. Parasitic worm infestation [1F90] [24]
Safinamide DM0YWJC Moderate Additive serotonergic effects by the combination of Citalopram derivative 1 and Safinamide. Parkinsonism [8A00] [56]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Rasagiline. Parkinsonism [8A00] [43]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Pimavanserin. Parkinsonism [8A00] [24]
Apomorphine DMX38HQ Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Apomorphine. Parkinsonism [8A00] [24]
Abametapir DM2RX0I Moderate Decreased metabolism of Citalopram derivative 1 caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [61]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Citalopram derivative 1 and Lindane. Pediculosis [1G00] [62]
Esomeprazole DM7BN0X Major Decreased metabolism of Citalopram derivative 1 caused by Esomeprazole mediated inhibition of CYP450 enzyme. Peptic ulcer [DA61] [35]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Famotidine. Peptic ulcer [DA61] [26]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Macimorelin. Pituitary gland disorder [5A60-5A61] [63]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Lefamulin. Pneumonia [CA40] [24]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Choline salicylate. Postoperative inflammation [1A00-CA43] [27]
Ketorolac DMI4EL5 Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Ketorolac. Postoperative inflammation [1A00-CA43] [27]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Bromfenac. Postoperative inflammation [1A00-CA43] [27]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Citalopram derivative 1 caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [35]
Ritodrine DM4V6RL Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Ritodrine. Preterm labour/delivery [JB00] [32]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Degarelix. Prostate cancer [2C82] [24]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and ABIRATERONE. Prostate cancer [2C82] [24]
Nilutamide DMFN07X Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Nilutamide. Prostate cancer [2C82] [24]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Enzalutamide. Prostate cancer [2C82] [24]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Relugolix. Prostate cancer [2C82] [24]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Bicalutamide. Prostate cancer [2C82] [24]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Levomepromazine. Psychotic disorder [6A20-6A25] [24]
Fluphenazine DMIT8LX Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Fluphenazine. Psychotic disorder [6A20-6A25] [24]
Triflupromazine DMKFQJP Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Triflupromazine. Psychotic disorder [6A20-6A25] [24]
Treprostinil DMTIQF3 Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Treprostinil. Pulmonary hypertension [BB01] [27]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Epoprostenol. Pulmonary hypertension [BB01] [27]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Iloprost. Pulmonary hypertension [BB01] [27]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Citalopram derivative 1 and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [64]
Sorafenib DMS8IFC Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Sorafenib. Renal cell carcinoma [2C90] [24]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Gatifloxacin. Respiratory infection [CA07-CA4Z] [24]
Meloxicam DM2AR7L Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Meloxicam. Rheumatoid arthritis [FA20] [27]
Sulindac DM2QHZU Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Sulindac. Rheumatoid arthritis [FA20] [27]
Celecoxib DM6LOQU Moderate Decreased metabolism of Citalopram derivative 1 caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [65]
Oxaprozin DM9UB0P Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Oxaprozin. Rheumatoid arthritis [FA20] [27]
Flurbiprofen DMGN4BY Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Flurbiprofen. Rheumatoid arthritis [FA20] [27]
Fenoprofen DML5VQ0 Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Fenoprofen. Rheumatoid arthritis [FA20] [27]
Indomethacin DMSC4A7 Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Indomethacin. Rheumatoid arthritis [FA20] [27]
Tolmetin DMWUIJE Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Tolmetin. Rheumatoid arthritis [FA20] [27]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Quetiapine. Schizophrenia [6A20] [24]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Mesoridazine. Schizophrenia [6A20] [24]
Thioridazine DM35M8J Major Decreased metabolism of Citalopram derivative 1 caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [66]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Citalopram derivative 1 caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [26]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Iloperidone. Schizophrenia [6A20] [24]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Paliperidone. Schizophrenia [6A20] [24]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Haloperidol. Schizophrenia [6A20] [24]
Perphenazine DMA4MRX Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Perphenazine. Schizophrenia [6A20] [24]
Chlorpromazine DMBGZI3 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Chlorpromazine. Schizophrenia [6A20] [24]
Clozapine DMFC71L Major Decreased metabolism of Citalopram derivative 1 caused by Clozapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [67]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Trifluoperazine. Schizophrenia [6A20] [24]
Ziprasidone DMM58JY Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Ziprasidone. Schizophrenia [6A20] [24]
Risperidone DMN6DXL Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Risperidone. Schizophrenia [6A20] [24]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Amisulpride. Schizophrenia [6A20] [24]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Asenapine. Schizophrenia [6A20] [24]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Pimozide. Schizophrenia [6A20] [24]
Salicyclic acid DM2F8XZ Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Salicyclic acid. Seborrhoeic dermatitis [EA81] [37]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Fentanyl. Sensation disturbance [MB40] [29]
Sufentanil DMU7YEL Major Additive serotonergic effects by the combination of Citalopram derivative 1 and Sufentanil. Sensation disturbance [MB40] [29]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Vardenafil. Sexual dysfunction [HA00-HA01] [24]
Voxelotor DMCS6M5 Minor Decreased metabolism of Citalopram derivative 1 caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [28]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Citalopram derivative 1 caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [49]
Larotrectinib DM26CQR Minor Decreased metabolism of Citalopram derivative 1 caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [28]
Armodafinil DMGB035 Major Decreased metabolism of Citalopram derivative 1 caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [35]
Epirubicin DMPDW6T Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [24]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [24]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [24]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [24]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Pitolisant. Somnolence [MG42] [24]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [24]
Topiramate DM82Z30 Moderate Antagonize the effect of Citalopram derivative 1 when combined with Topiramate. Substance abuse [6C40] [30]
Warfarin DMJYCVW Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Warfarin. Supraventricular tachyarrhythmia [BC81] [27]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Ibutilide. Supraventricular tachyarrhythmia [BC81] [24]
Adenosine DMM2NSK Major Increased risk of ventricular arrhythmias by the combination of Citalopram derivative 1 and Adenosine. Supraventricular tachyarrhythmia [BC81] [68]
Plicamycin DM7C8YV Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Plicamycin. Testicular cancer [2C80] [27]
Fostamatinib DM6AUHV Moderate Decreased clearance of Citalopram derivative 1 due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [69]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Caplacizumab. Thrombocytopenia [3B64] [27]
Anagrelide DMSQ8MD Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Anagrelide. Thrombocytosis [3B63] [24]
Apixaban DM89JLN Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Apixaban. Thrombosis [DB61-GB90] [27]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Cangrelor. Thrombosis [DB61-GB90] [27]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Brilinta. Thrombosis [DB61-GB90] [27]
Argatroban DMFI46A Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Argatroban. Thrombosis [DB61-GB90] [27]
Dicumarol DMFQCB1 Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Dicumarol. Thrombosis [DB61-GB90] [37]
Clopidogrel DMOL54H Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Clopidogrel. Thrombosis [DB61-GB90] [27]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Lenvatinib. Thyroid cancer [2D10] [24]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Cabozantinib. Thyroid cancer [2D10] [24]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Papaverine. Tonus and reflex abnormality [MB47] [70]
Tizanidine DMR2IQ4 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Tizanidine. Tonus and reflex abnormality [MB47] [24]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Citalopram derivative 1 and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [64]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Tacrolimus. Transplant rejection [NE84] [24]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Citalopram derivative 1 and Tolbutamide. Type 2 diabetes mellitus [5A11] [22]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Citalopram derivative 1 and Chlorpropamide. Type 2 diabetes mellitus [5A11] [22]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Citalopram derivative 1 and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [22]
Astemizole DM2HN6Q Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Astemizole. Vasomotor/allergic rhinitis [CA08] [24]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [24]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Citalopram derivative 1 and Cetirizine. Vasomotor/allergic rhinitis [CA08] [71]
Betrixaban DM2C4RF Moderate Increased risk of bleeding by the combination of Citalopram derivative 1 and Betrixaban. Venous thromboembolism [BD72] [27]
Disopyramide DM5SYZP Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Disopyramide. Ventricular tachyarrhythmia [BC71] [24]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Procainamide. Ventricular tachyarrhythmia [BC71] [24]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Propafenone. Ventricular tachyarrhythmia [BC71] [24]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Citalopram derivative 1 and Flecainide. Ventricular tachyarrhythmia [BC71] [24]
⏷ Show the Full List of 402 DDI Information of This Drug

References

1 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
2 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3 Cotgreave I, Moldeus P, Schuppe I: The metabolism of N-acetylcysteine by human endothelial cells. Biochem Pharmacol. 1991 Jun 21;42(1):13-6. doi: 10.1016/0006-2952(91)90674-t.
4 Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
5 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
6 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
9 Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
10 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
11 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
12 Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
13 Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
14 Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
15 Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
16 Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
17 Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
18 Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
19 Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.
20 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
21 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
22 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
23 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
24 Canadian Pharmacists Association.
25 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
26 Cerner Multum, Inc. "Australian Product Information.".
27 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
28 Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
29 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
30 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
31 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
32 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
33 Gammon GD, Brown TE "Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder." J Child Adolesc Psychopharmacol 3 (1993): 1-10. [PMID: 19630593]
34 Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
35 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide).".
36 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
37 Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
38 Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
39 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
40 Richards S, Umbreit JN, Fanucchi MP, Giblin J, Khuri F "Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan." South Med J 96 (2003): 1031-3. [PMID: 14570350]
41 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
42 Cerner Multum, Inc. "Canadian Product Information.".
43 Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20. [PMID: 8227489]
44 Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
45 Moller SE, Larsen F, Khant AZ, Rolan PE "Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects." J Clin Psychopharmacol 21 (2001): 493-9. [PMID: 11593075]
46 Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
47 Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
48 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
49 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
50 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
51 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
52 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
53 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
54 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
55 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
56 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
57 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
58 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
59 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
60 Caraco Y, Sheller J, Wood AJJ "Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects." J Pharmacol Exp Ther 290 (1999): 413-22. [PMID: 10381807]
61 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
62 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
63 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
64 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
65 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
66 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
67 Borba CP, Henderson DC "Citalopram and clozapine: Potential drug interaction." J Clin Psychiatry 61 (2000): 301-2. [PMID: 10830154]
68 Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
69 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
70 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
71 Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.